Skip to main content
Equibles
ALEC logo

ALEC · Alector, Inc. · Earnings Call Transcripts & Audio

Track ALEC — free

Use ALEC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ALEC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.18 +0.04 (+1.87%)
Russell 2000 member Rebalance outlook locked
Market Cap
$241.18M
Shares
111.66M

Alector, Inc. Earnings Call Transcripts

Quarterly earnings calls for Alector, Inc. (ALEC), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼29.6% $56.21M $1.38M '23 Q2 23-08-03 ▼38.7% $9.11M −$44.48M '23 Q3 23-11-07 ▲5.6% $15.23M −$41.43M '23 Q4 24-01-16 ▼3.9% $15.90M −$36.08M '24 Q1 24-05-08 ▼73.2% $15.08M −$38.68M '24 Q2 24-08-07 ▲256.1% $54.23M −$2.07M '24 Q4 25-02-26 LATEST ▼47.8% $7.87M −$30.52M '25 Q2 25-08-07
Earnings call
FY25 · Q2
2025-08-07
Alector, Inc. (ALEC) Q2 2025 Earnings Call Transcript
Confident tone FTD-GRN disease background and unmet need AL-101 early Alzheimer's Phase 2 Regulatory strategy and FDA engagement
Revenue
$7.87M
▼ 47.8% YoY
Diluted EPS
$-0.30
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-26
Alector, Inc. (ALEC) Q4 2024 Earnings Call Transcript
Positive tone Latozinemab Phase 3 INFRONT-3 in FTD granulin Alector Brain Carrier (ABC) platform AL101 in early Alzheimer's disease
Revenue
$54.23M*
▲ 256.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q2
2024-08-07
Alector, Inc. (ALEC) Q2 2024 Earnings Call Transcript
Confident tone TREM2 mechanism / microglia biology differentiation INVOKE-2 Phase 2 AL002 data readout Latozinemab / INFRONT-3 pivotal Phase 3 in FTD-GRN
Revenue
$15.08M
▼ 73.2% YoY
Diluted EPS
$-0.40
▼ 2100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Alector, Inc. (ALEC) Q1 2024 Earnings Call
Revenue
$15.90M
▼ 3.9% YoY
Diluted EPS
$-0.38
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-01-16
Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript
Positive tone AL002 / INVOKE-2 Phase 2 in Alzheimer's AL101 / PROGRESS-AD Phase 2 in early Alzheimer's Immuno-neurology / microglia mechanism
Revenue
$15.23M*
▲ 5.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Alector, Inc. (ALEC) Q3 2023 Earnings Call
Revenue
$9.11M
▼ 38.7% YoY
Diluted EPS
$-0.53
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Alector, Inc. (ALEC) Q2 2023 Earnings Call Transcript
Revenue
$56.21M
▼ 29.6% YoY
Diluted EPS
$0.02
▼ 83.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–7 of 7 earnings calls
Key facts CIK 1653087 CUSIP 014442107 13F (30d) 7 filings 7 filers Visit website Investor relations